A panel of expert advisers on Friday
unanimously agreed that a late-stage clinical trial of Eisai
and Biogen s Leqembi verified the benefit of
the treatment for Alzheimer s disease, clearing the way. | June 9, 2023
Wide coverage of Alzheimer s drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University. | May 11, 2023
CAMBRIDGE, Mass., March 16, 2023 Biogen Inc. today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency , and the European. | March 16, 2023
Biogen Inc on Thursday forecast
2022 profit well below Wall Street estimates as sales of its new
Alzheimer s disease drug stall, and said it was considering
deals of all sizes. The U.S.. | February 3, 2022